Tempus AI (NASDAQ:TEM) Stock Price Up 0.1% – Here’s Why

Tempus AI, Inc. (NASDAQ:TEM) shares traded up 0.1% on Friday . The company traded as high as $55.00 and last traded at $54.87. 5,948,954 shares traded hands during trading, a decline of 32% from the average session volume of 8,785,969 shares. The stock had previously closed at $54.84.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on TEM. Needham & Company LLC restated a “buy” rating and issued a $56.00 price target on shares of Tempus AI in a research note on Tuesday, January 14th. Bank of America upped their price target on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Piper Sandler reissued a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Loop Capital reduced their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Finally, Guggenheim started coverage on shares of Tempus AI in a research report on Monday, December 9th. They set a “buy” rating and a $74.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $56.36.

Tempus AI Stock Performance

The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The firm has a 50 day moving average of $44.36 and a 200-day moving average of $47.68.

Insider Transactions at Tempus AI

In other news, major shareholder Bradley A. Keywell sold 395,800 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the sale, the insider now directly owns 16,164,449 shares of the company’s stock, valued at $694,263,084.55. This represents a 2.39 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Eric P. Lefkofsky sold 85,788 shares of the firm’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $53.39, for a total transaction of $4,580,221.32. Following the completion of the transaction, the chief executive officer now directly owns 5,771,787 shares of the company’s stock, valued at approximately $308,155,707.93. This trade represents a 1.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,862,758 shares of company stock valued at $79,585,675.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds have recently bought and sold shares of the business. First Horizon Advisors Inc. bought a new stake in shares of Tempus AI in the 3rd quarter worth about $30,000. Geode Capital Management LLC increased its stake in Tempus AI by 0.4% during the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after acquiring an additional 539 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in Tempus AI during the fourth quarter valued at approximately $67,000. Vestor Capital LLC bought a new stake in shares of Tempus AI in the 3rd quarter valued at approximately $153,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Tempus AI by 10.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock worth $1,686,000 after purchasing an additional 2,765 shares during the period. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.